Cobimetinib

LuciCob is a kinase inhibitor indicated:

For the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib.

As a single agent for the treatment of adult patients with histiocytic neoplasms.

DOSAGE AND ADMINISTRATION

Confirm the presence of BRAF V600E or V600K mutation in tumor specimens prior to initiation of LuciCob with vemurafenib for patients with melanoma.

The recommended dose is 60 mg orally once daily for the first 21 days of each 28-day cycle until disease progression or unacceptable toxicity. Take LuciCob with or without food.